<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="83925">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01839149</url>
  </required_header>
  <id_info>
    <org_study_id>TRIG-05</org_study_id>
    <nct_id>NCT01839149</nct_id>
  </id_info>
  <brief_title>TI-001 (Intranasal Oxytocin) for Treatment of Chronic Migraine</brief_title>
  <official_title>A Phase 2, Enriched-enrollment, Randomized-withdrawal, Double-blinded, Placebo-Controlled Study to Assess the Efficacy, Tolerability, and Safety of Intranasal Oxytocin in Subjects With Chronic Migraine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Trigemina, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Trigemina, Inc</source>
  <oversight_info>
    <authority>Chile: Institute of Public Health (Instituto de Salud Pública de Chile)</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the use of oxytocin, given as a nasal spray, for treatment of chronic
      migraine.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Mean reduction in migraine headache days</measure>
    <time_frame>Baseline and 28 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Baseline is the 28-day screening period before enrollment in the study</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in migraine pain scores measured with a 4-point verbal rating scale</measure>
    <time_frame>baseline (before study drug administration) and 2 hours after dosing</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measured for every migraine episode during the open-label phase that consists of 28 days of active treatment for all enrolled subjects and during the randomized, double-blind phase.  Subjects are randomzied to either placebo or active and treated for 28-days during the double-blind phase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of nausea</measure>
    <time_frame>28 days (double-blind treatment period)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of photophobia</measure>
    <time_frame>28 days (double-blind treatment period)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of phonophobia</measure>
    <time_frame>28 days (double-blind treatment period)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of migraine episodes</measure>
    <time_frame>28 days (double-blind treatment period)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to study discontinuation due to any cause</measure>
    <time_frame>28 days (double-blind treatment period)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of adverse events</measure>
    <time_frame>56 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>This study has an open-label phase of 28 days wherein all subjects receive active drug and dose titrate to effect.  Then they are randomized to active or placebo for an additional 28 days of treatment.  Therefore safety is measured for the entire 56 days.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Interleukin-6 (IL-6) levels as a marker of response</measure>
    <time_frame>measured at screening only</time_frame>
    <safety_issue>No</safety_issue>
    <description>The screening period of this study is 28 days. But this blood test is done only once any time during the screening period before first dose.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Chronic Migraine</condition>
  <arm_group>
    <arm_group_label>TI-001 (intranasal oxytocin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TI-001 is intranasal oxytocin administered at 15 to 60 IU per dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for TI-001 is the same intranasal formulation without oxytocin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TI-001</intervention_name>
    <description>TI-001 is intranasal oxytocin administered at 15 to 60 IU per dose.</description>
    <arm_group_label>TI-001 (intranasal oxytocin)</arm_group_label>
    <other_name>Intranasal oxytocin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men and women, aged 18 to 80 years

          2. Primary diagnosis of chronic migraine based on the International Headache Society
             definition as defined below:

               1. Migraine headache without aura occurring on ≥15 days per month for &gt; 3 months
                  and fulfilling criteria b-d below:

               2. Headache has ≥ 2 of the following criteria:

             i. Unilateral location ii. Pulsating quality iii. Severe pain intensity iv.
             Aggravation by or causing avoidance of routine physical activity c. During headache ≥
             1 of the following: i. Nausea and/or vomiting ii. Photophobia and phonophobia d. Not
             attributed to another disorder

          3. Currently experiencing migraine headaches of at least 4 hours in duration, which are
             severe in pain intensity while on standard of care (eg, triptans and ergotamines)

        Exclusion Criteria:

          1. Known allergy to oxytocin

          2. History of addictive behavior (eg, alcoholism, drug abuse) or severe mood disorder

          3. History of clinically significant, functionally impairing cardiovascular or pulmonary
             disease or any other disease that might confound study results

          4. Have basilar or hemiplegic migraines

          5. Have substantial cognitive or memory impairment due to any cause (eg, Alzheimer's or
             dementia)

          6. Have a nasal obstruction due to any cause

          7. Are pregnant or breast feeding

          8. Require ongoing use of steroidal or nonsteroidal anti-inflammatory drugs

          9. Are unable or unwilling to provide informed consent or to follow study procedures
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raquel Izumi, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Trigemina, Inc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eugenio Silva</last_name>
    <phone>56 9 9279 3451</phone>
    <email>esilva@trigemina.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maria Luisa Bustos</last_name>
    <phone>56 9 9799 0956</phone>
    <email>mlbustos@trigemina.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <address>
        <city>Sherwood</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Chile</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 12, 2014</lastchanged_date>
  <firstreceived_date>April 17, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Refractory Chronic Migraine</keyword>
  <keyword>Medically Intractable Chronic Migraine</keyword>
  <keyword>Oxytocin</keyword>
  <keyword>Intranasal oxytocin</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
